Contineum Therapeutics, Inc. Class A (CTNM)

In December 2025, Contineum Therapeutics announced and priced an upsized $90.0 million public offering. In November 2025, the company reported that its Phase 2 VISTA trial of PIPE-307 for RRMS did not meet its primary or secondary efficacy endpoints. In January 2026, Morgan Stanley and Wall Street Zen downgraded Contineum Therapeutics, while Wall Street Zen upgraded the company to a "Hold" rating in December 2025, and the company received an upgrade to a Zacks Rank #2 (Buy). The company's share price experienced a decline of 21.06% between January 2, 2025, and December 31, 2025, with a 52-week range between $3.35 and $15.25.

As a clinical-stage biopharmaceutical company without commercialized products, Contineum Therapeutics, Inc. has no established demand seasonality. The company's focus is on research and development, with potential future demand driven by successful clinical trials, regulatory approvals, and market adoption of its therapies.

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule therapies for neuroscience, inflammation, and immunology indications with unmet medical needs in the United States. Its major product candidates include PIPE-791 for IPF, PrMS, and chronic pain; PIPE-307 in Phase 2 trials for RRMS and MDD; and CTX-343, a peripherally restricted LPA1R antagonist in earlier development.

Contineum Therapeutics, Inc. is headquartered in San Diego, California, United States, focusing on developing therapies for indications with high unmet needs primarily within the United States.

Contineum Therapeutics has maintained an average recommendation of "Moderate Buy" from analysts, with a consensus price target of $19.00. However, the company's reputation was likely impacted by the disappointing topline results from its Phase 2 PIPE-307 VISTA trial in November 2025, which failed to meet its primary or secondary efficacy endpoints for relapsing-remitting multiple sclerosis.

Contineum Therapeutics, Inc. is owned by a mix of institutional, insider, and retail investors. Institutional shareholders hold approximately 59.89% of the company's stock, while insiders own about 9.25%, and retail investors hold 30.86%. Major institutional owners include RA Capital Management, L.P., Johnson & Johnson, and Suvretta Capital Management, LLC. Johnson & Johnson is the largest individual shareholder, owning 1.98 million shares, representing 6.78% of the company.